{"title":"Effect of statin on mortality in diabetic patients with COVID-19: A systematic review and meta-analysis","authors":"Kamran Roudini, Azin Alizadehasl, DavoodKhoda Amorzideh, Nashmil Ghadimi, Hossein Hosseinifard, Sara Kaveh, NiloufarAkbari Parsa","doi":"10.4103/rcm.rcm_39_22","DOIUrl":null,"url":null,"abstract":"Context: It seems that the threat of death increases among diabetic patients with coronavirus infection disease-2019 (COVID-19). Statins have anti-inflammatory and anti-thrombogenic properties along with lowering blood cholesterol. Therefore, statins could be considered as an important factor in reducing the mortality rates in diabetic patients with COVID-19. This systematic review and meta-analysis study was performed to investigate the effect of statin on mortality in diabetic patients with COVID-19. Evidence Acquisition: This study was done based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Electronic databases such as PubMed, Embase, Scopus, Web of Science, and Cochrane Library were searched from December 2019 until the end of September 2022. Meta-analysis was used by the comprehensive meta-analysis software to combine the results. A funnel plot and Egger’s regression test were used to investigate the publication bias. Results: Six studies were included in the meta-analysis. Nine thousand five hundred and thirty-three diabetic patients with COVID-19 were studied. The heterogeneity between studies was significant. According to the meta-analysis, using the random-effects model, we found that the rate of mortality due to COVID-19 in diabetic patients who used statins was 9% lower than other patients. Publication bias between studies included in the meta-analysis was not significant. Conclusions: In this study, there was no significant difference between the mortality rates of diabetic people with COVID-19 who used statins and individuals who did not consume statins – this difference was just 9%. Therefore, it could be said that more clinical trials are needed to ensure the clinical efficacy of statins among diabetic patients with COVID-19.","PeriodicalId":21031,"journal":{"name":"Research in Cardiovascular Medicine","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research in Cardiovascular Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/rcm.rcm_39_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Context: It seems that the threat of death increases among diabetic patients with coronavirus infection disease-2019 (COVID-19). Statins have anti-inflammatory and anti-thrombogenic properties along with lowering blood cholesterol. Therefore, statins could be considered as an important factor in reducing the mortality rates in diabetic patients with COVID-19. This systematic review and meta-analysis study was performed to investigate the effect of statin on mortality in diabetic patients with COVID-19. Evidence Acquisition: This study was done based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Electronic databases such as PubMed, Embase, Scopus, Web of Science, and Cochrane Library were searched from December 2019 until the end of September 2022. Meta-analysis was used by the comprehensive meta-analysis software to combine the results. A funnel plot and Egger’s regression test were used to investigate the publication bias. Results: Six studies were included in the meta-analysis. Nine thousand five hundred and thirty-three diabetic patients with COVID-19 were studied. The heterogeneity between studies was significant. According to the meta-analysis, using the random-effects model, we found that the rate of mortality due to COVID-19 in diabetic patients who used statins was 9% lower than other patients. Publication bias between studies included in the meta-analysis was not significant. Conclusions: In this study, there was no significant difference between the mortality rates of diabetic people with COVID-19 who used statins and individuals who did not consume statins – this difference was just 9%. Therefore, it could be said that more clinical trials are needed to ensure the clinical efficacy of statins among diabetic patients with COVID-19.
背景:患有冠状病毒感染-2019 (COVID-19)的糖尿病患者的死亡威胁似乎有所增加。他汀类药物具有抗炎和抗血栓形成的特性以及降低血液中的胆固醇。因此,他汀类药物可被认为是降低糖尿病合并COVID-19患者死亡率的重要因素。本系统综述和荟萃分析研究旨在探讨他汀类药物对糖尿病合并COVID-19患者死亡率的影响。证据获取:本研究是根据系统评价和荟萃分析指南的首选报告项目完成的。从2019年12月到2022年9月底,检索了PubMed、Embase、Scopus、Web of Science和Cochrane Library等电子数据库。采用综合meta分析软件对结果进行综合分析。采用漏斗图和Egger回归检验检验发表偏倚。结果:6项研究被纳入meta分析。对9533例糖尿病合并COVID-19患者进行了研究。研究间的异质性显著。根据meta分析,使用随机效应模型,我们发现使用他汀类药物的糖尿病患者因COVID-19的死亡率比其他患者低9%。纳入meta分析的研究之间的发表偏倚不显著。结论:在这项研究中,使用他汀类药物的COVID-19糖尿病患者和未使用他汀类药物的患者的死亡率没有显著差异,差异仅为9%。因此,需要更多的临床试验来确保他汀类药物在糖尿病合并COVID-19患者中的临床疗效。